Zurcher Kantonalbank Zurich Cantonalbank trimmed its position in shares of Pfenex Inc (NYSEAMERICAN:PFNX) by 24.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,700 shares of the biotechnology company’s stock after selling 3,100 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Pfenex were worth $65,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA increased its stake in Pfenex by 2,127.7% in the first quarter. BNP Paribas Arbitrage SA now owns 6,037 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 5,766 shares during the last quarter. Weiss Asset Management LP purchased a new position in Pfenex in the first quarter valued at approximately $81,000. Millennium Management LLC increased its stake in Pfenex by 496.1% in the fourth quarter. Millennium Management LLC now owns 75,364 shares of the biotechnology company’s stock valued at $240,000 after purchasing an additional 62,722 shares during the last quarter. Falcon Point Capital LLC increased its stake in Pfenex by 3.5% in the first quarter. Falcon Point Capital LLC now owns 83,005 shares of the biotechnology company’s stock valued at $513,000 after purchasing an additional 2,800 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Pfenex by 16.9% in the fourth quarter. Bank of New York Mellon Corp now owns 95,602 shares of the biotechnology company’s stock valued at $305,000 after purchasing an additional 13,795 shares during the last quarter.
Separately, Zacks Investment Research raised Pfenex from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a report on Thursday, August 15th.
Pfenex stock traded down $0.36 during midday trading on Friday, reaching $6.48. The company’s stock had a trading volume of 1,039 shares, compared to its average volume of 152,694. Pfenex Inc has a fifty-two week low of $3.13 and a fifty-two week high of $7.64.
Pfenex (NYSEAMERICAN:PFNX) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.07. The business had revenue of $2.81 million during the quarter, compared to analyst estimates of $5.65 million.
Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study.
Featured Story: Green Investing
Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.